Technology Review profiles next-gen sequencing company Pacific Biosciences, which has raised $178 million to develop its zero mode waveguide technology. According to the article, the company's got 12 prototype instruments churning out data. And with read lengths targeting thousands of bases, PacBio has its eye on the medical market, where "we'll be able to detect rare mutations with unprecedented accuracy," says CTO Steve Turner.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.